In different studies, it has been shown that "antioxidant" utilization has favorable therapeutic effects not only on control of acute symptoms but also on prevention of delayed problems from acute and chronic pyelonephritis. According to the efficacy of acetylcysteine as a potent antioxidant, safety of this drug and side effects of similar or either less than placebo, this study was designed to evaluate the efficacy of this drug on inflammatory biomarkers of pediatric acute pyelonephritis. It is a triple-blind placebo controlled study on a population of 64 patients 1-16 years old that have "definite" or "probable" diagnosis of acute pyelonephritis in "Mofid" hospital. After randomization, patients will be given acetylcysteine or placebo with dosing according to their weight. Results of treatment are evaluated according to serum procalcitonin, C reactive protein and leukocyte count before drug prescription (baseline) and 5 days after drug prescription. Side effects are also recorded in both groups. Patients will be receiving their routine antimicrobial drugs in addition to acetylcysteine.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
70
Pediatric Infections Research Center
Tehran, Tehran Province, Iran
Serum procalcitonin
Time frame: Change from baseline serum procalcitonin at 5 days
Serum C Reactive Protein
Time frame: Change from baseline serum C Reactive Protein at 5 days
Leukocyte count
Time frame: Change from baseline leukocyte count at 5 days
Probable adverse effects (nausea, vomiting, bad tasting, stomatitis, ...)
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.